{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:36:02Z","timestamp":1787236562503,"version":"build-2736575974"},"reference-count":19,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T00:00:00Z","timestamp":1423008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2015,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    ADS\u20105102 is a long\u2010acting, extended\u2010release capsule formulation of amantadine HCl administered once daily at bedtime. This study investigated the safety, efficacy, and tolerability of ADS\u20105102 in Parkinson's disease (PD) patients with levodopa\u2010induced dyskinesia. This was a randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group study of 83 PD patients with troublesome dyskinesia assigned to placebo or one of three doses of ADS\u20105102 (260 mg, 340 mg, 420 mg) administered daily at bedtime for 8 weeks. The primary efficacy analysis compared change from baseline to week 8 in Unified Dyskinesia Rating Scale (UDysRS) total score for 340 mg ADS\u20105102 versus placebo. Secondary outcome measures included change in UDysRS for 260 mg, 420 mg, Fatigue Severity Scale (FSS), Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS\u2010UPDRS), patient diary, Clinician's Global Impression of Change, and Parkinson's Disease Questionnaire (PDQ\u201039). ADS\u20105102 340 mg significantly reduced dyskinesia versus placebo (27% reduction in UDysRS,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.005). In addition, ADS\u20105102 significantly increased ON time without troublesome dyskinesia, as assessed by PD patient diaries, at 260 mg (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.004), 340 mg (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.008) and 420 mg (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009=\u20090.018). Adverse events (AEs) were reported for 82%, 80%, 95%, and 90% of patients in the placebo, 260\u2010mg, 340\u2010mg, and 420\u2010mg groups, respectively. Constipation, hallucinations, dizziness, and dry mouth were the most frequent AEs. Study withdrawal rates were 9%, 15%, 14%, and 40% for the placebo, 260\u2010mg, 340\u2010mg, and 420\u2010mg groups, respectively. All study withdrawals in the active treatment groups were attributable to AEs. ADS\u20105102 was generally well tolerated and resulted in significant and dose\u2010dependent improvements in dyskinesia in PD patients. \u00a9 2015 Adamas Pharmaceuticals, Inc.\n                    <jats:italic>Movement<\/jats:italic>\n                    Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.\n                  <\/jats:p>","DOI":"10.1002\/mds.26159","type":"journal-article","created":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T01:19:12Z","timestamp":1423012752000},"page":"788-795","source":"Crossref","is-referenced-by-count":134,"title":["Amantadine extended release for levodopa\u2010induced dyskinesia in Parkinson's disease (EASED Study)"],"prefix":"10.1002","volume":"30","author":[{"given":"Rajesh","family":"Pahwa","sequence":"first","affiliation":[{"name":"University of Kansas Medical Center Kansas City Kansas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline M.","family":"Tanner","sequence":"additional","affiliation":[{"name":"The Parkinson's Institute, Sunnyvale, CA, San Francisco Veterans Affairs Medical Center and University of California\u2013San Francisco San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Hauser","sequence":"additional","affiliation":[{"name":"University of South Florida Tampa Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kapil","family":"Sethi","sequence":"additional","affiliation":[{"name":"Georgia Regents University Augusta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Isaacson","sequence":"additional","affiliation":[{"name":"Parkinson's Disease and Movement Disorders Center Boca Raton Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Truong","sequence":"additional","affiliation":[{"name":"Parkinson's &amp; Movement Disorder Institute Fountain Valley California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Struck","sequence":"additional","affiliation":[{"name":"Iowa Health Physicians Des Moines Iowa USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April E.","family":"Ruby","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc. Emeryville California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie L.","family":"McClure","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc. Emeryville California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory T.","family":"Went","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc. Emeryville California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Jean","family":"Stempien","sequence":"additional","affiliation":[{"name":"Adamas Pharmaceuticals, Inc. Emeryville California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,2,4]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2012.05.029"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1090"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1969.03160070046011"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5.1323"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.56.11.1383"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25122"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23034"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.55.3.181"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22340"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20248"},{"key":"e_1_2_8_12_1","unstructured":"ICH Harmonised Tripartite Guideline E9: Statistical Principles for Clinical Trials. 1998:Current Step 4 version."},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-3758(01)00077-5"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2010.166"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25003"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.25321"},{"key":"e_1_2_8_17_1","first-page":"307","article-title":"Double blind study using amantadine hydrochloride in the therapy of Parkinson's disease","volume":"96","author":"Silver DE","year":"1971","journal-title":"Trans Am Neurol Assoc"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.19.2.226"},{"key":"e_1_2_8_19_1","first-page":"595","article-title":"Chemoprophylaxis of viral respiratory disease","author":"Jackson GG","year":"1967","journal-title":"Bull Pan Am Health Org"},{"key":"e_1_2_8_20_1","unstructured":"Merz Pharmaceuticals GmbH. PK\u2010Merz\u00aefilm\u2010coated tablet. 2003:11."}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26159","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.26159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26159","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/mds.26159","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.26159","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:26:20Z","timestamp":1760966780000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.26159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,4]]},"references-count":19,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,5]]}},"alternative-id":["10.1002\/mds.26159"],"URL":"https:\/\/doi.org\/10.1002\/mds.26159","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725349331.793504570","asserted-by":"object"},{"id-type":"doi","id":"10.3410\/f.725349331.793529089","asserted-by":"object"}]},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,4]]}}}